Neurocrine Biosciences Inc (NBIX)
140.06
+6.36
(+4.76%)
USD |
NASDAQ |
Apr 23, 16:00
140.06
0.00 (0.00%)
After-Hours: 20:00
Neurocrine Biosciences Enterprise Value: 12.44B for April 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 22, 2024 | 12.44B |
| April 19, 2024 | 12.27B |
| April 18, 2024 | 12.33B |
| April 17, 2024 | 12.40B |
| April 16, 2024 | 12.37B |
| April 15, 2024 | 12.25B |
| April 12, 2024 | 12.54B |
| April 11, 2024 | 12.66B |
| April 10, 2024 | 12.88B |
| April 09, 2024 | 12.96B |
| April 08, 2024 | 13.01B |
| April 05, 2024 | 12.96B |
| April 04, 2024 | 12.83B |
| April 03, 2024 | 12.83B |
| April 02, 2024 | 12.84B |
| April 01, 2024 | 13.21B |
| March 28, 2024 | 12.86B |
| March 27, 2024 | 12.85B |
| March 26, 2024 | 13.18B |
| March 25, 2024 | 13.09B |
| March 22, 2024 | 13.21B |
| March 21, 2024 | 13.44B |
| March 20, 2024 | 13.13B |
| March 19, 2024 | 13.16B |
| March 18, 2024 | 13.01B |
| Date | Value |
|---|---|
| March 15, 2024 | 12.98B |
| March 14, 2024 | 12.99B |
| March 13, 2024 | 13.25B |
| March 12, 2024 | 12.84B |
| March 11, 2024 | 12.93B |
| March 08, 2024 | 12.99B |
| March 07, 2024 | 12.60B |
| March 06, 2024 | 12.30B |
| March 05, 2024 | 12.44B |
| March 04, 2024 | 12.38B |
| March 01, 2024 | 12.20B |
| February 29, 2024 | 12.11B |
| February 28, 2024 | 12.54B |
| February 27, 2024 | 12.67B |
| February 26, 2024 | 12.63B |
| February 23, 2024 | 12.49B |
| February 22, 2024 | 12.41B |
| February 21, 2024 | 12.14B |
| February 20, 2024 | 12.34B |
| February 16, 2024 | 12.30B |
| February 15, 2024 | 12.47B |
| February 14, 2024 | 12.25B |
| February 13, 2024 | 12.46B |
| February 12, 2024 | 12.12B |
| February 09, 2024 | 12.30B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.464B
Minimum
Apr 30 2019
13.44B
Maximum
Mar 21 2024
9.247B
Average
8.923B
Median
Enterprise Value Benchmarks
| Globus Medical Inc | 6.837B |
| Inspire Medical Systems Inc | 6.203B |
| AIM ImmunoTech Inc | 8.578M |
| Protalix BioTherapeutics Inc | 61.89M |
| Armata Pharmaceuticals Inc | 159.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 147.70M |
| Revenue (Quarterly) | 515.20M |
| Total Expenses (Quarterly) | 364.90M |
| EPS Diluted (Quarterly) | 1.44 |
| Gross Profit Margin (Quarterly) | 98.35% |
| Profit Margin (Quarterly) | 28.67% |
| Earnings Yield | 1.73% |
| Operating Earnings Yield | 2.81% |
| Normalized Earnings Yield | 2.040 |